OTCMKTS:ENDV Endonovo Therapeutics (ENDV) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ENDV Stock Alerts $0.0026 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0025▼$0.002650-Day Range N/A52-Week Range$0.00▼$0.02Volume12,836 shsAverage Volume1.10 million shsMarket Capitalization$918,895.70P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Endonovo Therapeutics alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Endonovo Therapeutics Stock (OTCMKTS:ENDV)Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.Read More ENDV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENDV Stock News HeadlinesMarch 28, 2024 | globenewswire.comEndonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, IncMarch 4, 2024 | finance.yahoo.comEndonovo’s SofPulse® to Be Featured at Innovative Pain Management SolutionsApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 4, 2024 | globenewswire.comEndonovo's SofPulse® to Be Featured at Innovative Pain Management SolutionsDecember 4, 2023 | finance.yahoo.comEndonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 MillionNovember 21, 2023 | finance.yahoo.comEndonovo Therapeutics, Inc. (ENDV)November 15, 2023 | investing.comLexeo Therapeutics Inc (LXEO)October 13, 2023 | msn.comEndonovo receives Taiwanese approval for SofPulse technologyApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.October 12, 2023 | finance.yahoo.comEndonovo's SofPulse® Secures Taiwan FDA ApprovalAugust 22, 2023 | finance.yahoo.comEndonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA DistributionAugust 8, 2023 | finance.yahoo.comEndonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual UpdateJune 22, 2023 | finance.yahoo.comNew to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.June 22, 2023 | finance.yahoo.comNew to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.June 7, 2023 | finance.yahoo.comEndonovo Pending Agreement to Develop Telehealth DivisionMay 2, 2023 | finance.yahoo.comEndonovo Launches SofPulse® into the Veterans AdministrationApril 25, 2023 | finance.yahoo.comEndonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment StudiesApril 13, 2023 | finance.yahoo.comEndonovo Announces Partnership with Former NFL Dallas Cowboy Defensive LinemanApril 10, 2023 | finance.yahoo.comEndonovo Announces Partnership with Santana Lead Singer Andy VargasMarch 29, 2023 | finance.yahoo.comEndonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off CompanyMarch 23, 2023 | finance.yahoo.comEndonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in TaiwanMarch 15, 2023 | finance.yahoo.comOlympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder SurgeryMarch 9, 2023 | finance.yahoo.comEndonovo Therapeutics (OTCMKTS:ENDV) Reaches Distribution Agreement with Academy MedicalMarch 6, 2023 | finance.yahoo.comEndonovo Announces Distribution Agreement with Academy MedicalFebruary 28, 2023 | finance.yahoo.comEndonovo Announces Q&A with Newly-Appointed SofPulse® Medical Division President, Ira WeisbergJanuary 31, 2023 | finance.yahoo.comEndonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-OffJanuary 26, 2023 | finance.yahoo.comEndonovo Partners with International Distributor for SofPulse® LineSee More Headlines Receive ENDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolOTCMKTS:ENDV CUSIPN/A CIK1528172 Webwww.endonovo.com Phone(800) 489-4774Fax818-230-9899Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,480,000.00 Net Margins-1,717.21% Pretax Margin-1,717.21% Return on EquityN/A Return on Assets-408.63% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$140,000.00 Price / Sales6.56 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-0.02Miscellaneous Outstanding Shares349,390,000Free Float329,793,000Market Cap$918,895.70 OptionableNot Optionable Beta-1.41 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Alan Brian Collier (Age 58)Chairman & CEO Comp: $300kMr. Don CalabriaVice President of OperationsMr. Garry Michael KannHead of Corporate DevelopmentMr. Ira Weisberg (Age 75)President & Chief Commercial Officer of Medical Division Key CompetitorsAradigmOTCMKTS:ARDMQMagna-LabOTCMKTS:MAGAATivic Health SystemsNASDAQ:TIVCNon-Invasive Monitoring SystemsOTCMKTS:NIMUNuwellisNASDAQ:NUWEView All Competitors ENDV Stock Analysis - Frequently Asked Questions How have ENDV shares performed in 2024? Endonovo Therapeutics' stock was trading at $0.0087 at the start of the year. Since then, ENDV shares have decreased by 69.8% and is now trading at $0.0026. View the best growth stocks for 2024 here. What other stocks do shareholders of Endonovo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Ekso Bionics (EKSO), Geron (GERN), Marinus Pharmaceuticals (MRNS), Micron Technology (MU), Novavax (NVAX) and Exxon Mobil (XOM). How do I buy shares of Endonovo Therapeutics? Shares of ENDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ENDV) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endonovo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
